Diabetes & Wound Care Centers of America Launches New Specialty Health Clinic Chain for 2025
DWCC will partner with select hospitals, providing specialized diabetes management and advanced wound care services across the USA
LAS VEGAS - January 28, 2025 - Diabetes & Wound Care Centers of America (DWCC) today announced its plans to launch a chain of its clinics in 2025. DWCC is introducing its clinic model, effectively providing extremely specialized diabetes management and advanced wound care services to communities that previously had no, or few treatment resources.
DWCC treats a significant and common problem facing diabetes patients. The disease can damage a patient's skin and reduce its ability to heal itself. As a result, diabetes patients often develop hard-to-treat wounds that are painful and have the potential to become costly and even life-threatening if not addressed promptly and professionally.
The launch of the chain also offers a solution to a healthcare access problem that affects many Americans. Across the United States, complications from diabetes and treatment of such has imposed a strain on healthcare institutions. The Las Vegas-based company solves this problem through accessible healthcare. Executing this program involves initiating strategic partnerships with selected hospitals.
Diabetes care has previously been folded into existing healthcare systems. DWCC is changing this dynamic through specialized services. It has the ability to provide optimized outcomes and the highest standard of care for patients in need of professional care and measurable results.
'Despite recent healthcare advancements, many patients across the United States still face significant obstacles to accessing comprehensive care,' said Jeff Russell, President, and founder of DWCC, who brings decades of related expertise to his role. 'While hospitals work to meet the growing demand for specialized care, patients experience delayed treatment, worsened health outcomes, and higher costs.'
'We use the latest, state-of-the-art technologies to treat non-healing wounds by integrating skin substitutes, to name one example of our differentiated approach,' said Russell. 'We are incorporating innovative treatment strategies for problematic diabetes patients who are not seeing positive results with their previous or existing treatments.'
Russell added, 'Our focus is on secondary markets and rural markets that heretofore have not had gold standard treatments for critical complications of diabetes and will just not heal. We will address those patients exposed to infections and in some cases, amputations.'
DWCC has designed healing program standards for diabetes management and chronic wound care, offering bespoke patient treatment services for optimized outcomes and an elevated standard of care, with the focus of delivering optimal results.
Country: United States
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
13 minutes ago
- USA Today
With a new COVID variant on the rise, which US states have the most cases?
Some states are being hit harder than others this summer as a new COVID-19 strain (XGF) continues to spread. Some regions of the U.S. are still experiencing higher rates of positive COVID tests than others, though reporting has slowed down enough nationwide that the Centers for Disease Control (CDC) has begun allowing more time to pass between certain types of updates, such as those on variant prevalence. Testing, cases, hospitalizations and deaths are still being recorded on a weekly basis, however, even amid the chaos of ever-changing strains, recommendations and cuts to vaccine development funding. Here's what to know about the latest data. How many COVID cases were reported nationwide? During the week ending on Aug. 2, 8.5% of the 25,731 Americans tested were positive for COVID, according to the CDC's latest data. This was 2% increase from the week prior. During the same period, only 0.3% of cases resulted in death and 0.9% resulted in an emergency room visit, a 0.1% decrease from the week prior for both categories. More: What is an mRNA vaccine, and why is it controversial? Where are the most COVID cases being reported? See map Western and southern states, including Washington, Oregon, Idaho, California, Nevada, Arizona, New Mexico, Texas, Oklahoma, Arkansas and Louisiana, had higher percentages of positive COVID tests during the week ending Aug. 2. What is the most common COVID variant? The CDC has moved to using longer data timeframes for COVID tracking due to low reporting from states. According to the latest data for the two weeks ending June 21, variant NB.1.8.1 remained the most common, accounting for 43% of cases, followed by LP.8.1 at 31% of cases and XFG at 14%. NB.1.8.1 experienced a meteoric rise to becoming the predominant variant, accounting for 0% of cases in April and only 10% in the last week of May, up to 24% at the beginning of June and 43% by the end. XFG, a combination of variants F.7 and LP.8.1.2, is on the rise as of late, having been responsible for 0% of U.S. cases through March, 11% by early June and 14% by late June.
Newsweek
4 hours ago
- Newsweek
Chocolate Recall Sparks Nationwide Warning to Customers
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Neuhaus Chocolates NV is recalling their Belgian Chocolate Moments Smurfs 'Popping Milk Chocolates with Cookies because the product contains wheat which was not declared on the packaging. Newsweek reached out to the company via email Monday for comment. Why It Matters Numerous recalls have been initiated this year due to the potential for damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or allergies every year. According to the U.S. Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. People with a wheat allergy could experience a "serious or life-threatening allergic reaction if they consume these products," the FDA warns. What To Know Neuhaus Chocolate can be seen related to a recall in August 2025. (Photo from the U.S. Food and Drug Administration) Neuhaus Chocolate can be seen related to a recall in August 2025. (Photo from the U.S. Food and Drug Administration) In the alert, the FDA says the recalled chocolates were distributed from July 21, 2025, until August 4, 2025, by Neuhaus stores in Virginia, New York, Pennsylvania, Maryland, Washington, D.C. and via their online store. The impacted batch numbers are 80108690 and 80108763 with a best use before date of January 13, 2026, the FDA alert says. There have been no reports of illnesses related to this recall and 150 units of the impacted products were sold, the FDA says. What People Are Saying The FDA in their alert in part: "The action was initiated after it was discovered during an internal check that product containing wheat was distributed in packaging that did not reveal the presence of wheat. Subsequent investigation indicates the problem was caused by an exceptional combination of circumstances in which the ERP (Enterprise Resource Planning) did not include the allergen on the packaging." In an email to Newsweek in January, the FDA said: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall; the FDA shares that release on our website as a public service. "The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall. "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled." Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts. What Happens Next Customers who have purchased the recalled product who have a wheat allergy are asked to return it to the original place of purchase and not to consume it, the FDA says. People with additional questions may contact the company via phone at +32 2 568 23 00 from 8 a.m. to 5 p.m. Central European Summer Time on weekdays or via email at customercare@
Yahoo
4 hours ago
- Yahoo
IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies
The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a strong pipeline of clinical trials, and growing regulatory approvals. Leading companies such as GlaxoSmithKline, Mirum Pharmaceuticals, Ipsen Pharma, Albireo, Takeda, and others are actively developing IBAT inhibitor therapies targeting conditions like PBC, PSC, ALGS, PFIC, and related diseases. LAS VEGAS, Aug 11, 2025 /PRNewswire/ -- DelveInsight's IBAT Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), metabolic dysfunction-associated steatohepatitis (MASH), chronic constipation, biliary atresia, Alagille syndrome (ALGS), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging IBAT inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the IBAT Inhibitors Market Report As per DelveInsight's analysis, the total market size of IBAT inhibitors in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), metabolic dysfunction-associated steatohepatitis (MASH), chronic constipation, biliary atresia, Alagille syndrome (ALGS), and others. Leading IBAT inhibitor companies, such as GlaxoSmithKline, Mirum Pharmaceuticals, Ipsen, Albireo, and others, are developing novel IBAT inhibitors that can be available in the IBAT inhibitors market in the coming years. Some of the key IBAT inhibitors in the pipeline include Linerixibat, Volixibat, Ritivixibat, and others. In March 2025, Takeda announced that Japan's MHLW approved LIVMARLI Oral Solution 10 mg/mL for the treatment of pruritus associated with cholestasis in ALGS and PFIC. In November 2024, Ipsen announced data at the AASLD assessing the long-term efficacy and safety of patients treated with BYLVAY from two Phase III open-label extension studies in PFIC and ALGS. In October 2024, Mirum Pharmaceuticals announced that the FDA granted a breakthrough therapy designation (BTD) to volixibat as a possible treatment for cholestatic pruritus in patients with PBC. Volixibat also received FTD from the FDA in 2016 for the treatment of NASH in patients with liver fibrosis. Discover which indication is expected to grab the major IBAT inhibitors market share @ IBAT Inhibitors Market Report IBAT Inhibitors Market Dynamics The market dynamics for IBAT inhibitors are shaped by a confluence of factors, including rising prevalence of rare cholestatic liver diseases, growing awareness of pediatric liver disorders, and the increasing regulatory support for rare disease therapeutics. The approval of two key drugs, LIVMARLI and BYLVAY, by the US FDA and European regulatory authorities has not only validated the therapeutic mechanism but also catalyzed investment and R&D activity in this niche segment. The market is expected to witness significant growth due to the unmet medical need in pediatric hepatology and the relatively limited competition within this orphan drug space. Both LIVMARLI and BYLVAY have demonstrated clinically meaningful reductions in pruritus and improvements in liver function biomarkers, supporting their adoption. Furthermore, these drugs benefit from orphan drug designation, which grants market exclusivity, reduced regulatory fees, and extended patent life, enhancing the commercial attractiveness for developers. Their use is currently being explored in additional indications, including biliary atresia and intrahepatic cholestasis of pregnancy, which could further expand their market potential. Despite the momentum, there are key challenges that could moderate growth. One is the high cost of therapy, which may limit access in markets with less robust healthcare reimbursement systems. Additionally, the rarity of target diseases necessitates specialized diagnostic capabilities and referral networks, which are underdeveloped in many regions. Market penetration in emerging economies remains limited, creating a disparity in treatment availability. Moreover, competition is expected to intensify as more players enter the space with either me-too IBAT inhibitors or gene therapy-based solutions aiming at disease modification. IBAT Inhibitors Treatment Market As of now, two IBAT inhibitors, LIVMARLI and BYLVAY (also marketed as KAYFANDA), have received regulatory approvals. LIVMARLI, an oral IBAT inhibitor available in both liquid and tablet forms, has been approved by the U.S. FDA for use in pediatric patients with cholestatic liver diseases. In the U.S., it is indicated for treating cholestatic pruritus in patients with Alagille syndrome (ALGS) aged three months and older, and in Europe for those aged two months and older. Additionally, it is approved in the U.S. for patients aged 12 months and older with progressive familial intrahepatic cholestasis (PFIC), and in Europe for patients aged three months and above. The drug is currently being studied in the Phase III EXPAND trial to assess its potential in broader settings of cholestatic pruritus, with enrollment expected to conclude by 2026. LIVMARLI has received Breakthrough Therapy designation in the U.S. for ALGS and PFIC2, and Orphan Drug Designation (ODD) for both ALGS and PFIC in the U.S. and Europe. Japan's Ministry of Health, Labour and Welfare (MHLW) granted it ODD for anticipated indications in ALGS and PFIC in December 2022. In April 2025, Mirum Pharmaceuticals announced FDA approval of a new tablet formulation of LIVMARLI for use in ALGS and PFIC, with commercial availability expected in June 2025 via the Mirum Access Plus program. Additionally, in November 2024, the company presented new clinical data on LIVMARLI at the AASLD Liver Meeting. BYLVAY is a potent, once-daily IBAT inhibitor that works locally in the small intestine with limited systemic absorption. It is approved in the U.S. for treating pruritus in PFIC patients aged three months and older, where it benefits from orphan drug exclusivity. First launched in the U.S. in 2021 for PFIC, BYLVAY is supported by programs to facilitate patient access and support. In the EU, it is approved for PFIC in children aged six months and above and is available in over nine countries, with reimbursement in key markets such as Germany, France, Italy, the UK, and Belgium. In June 2023, the U.S. FDA approved BYLVAY for treating cholestatic pruritus in ALGS patients aged 12 months and older. Subsequently, in September 2024, the European Commission approved the drug, under the brand name KAYFANDA, under exceptional circumstances for treating cholestatic pruritus in ALGS in children aged six months and above. Learn more about the IBAT inhibitors @ IBAT Inhibitors Analysis Key Emerging IBAT Inhibitors and Companies Key IBAT inhibitors in the pipeline include Volixibat (Mirum Pharmaceuticals), Linerixibat (GlaxoSmithKline), Ritivixibat (Ipsen/Albireo), and others. Volixibat is an orally administered, minimally absorbed drug designed to specifically block the ileal bile acid transporter (IBAT). By inhibiting IBAT, it disrupts the enterohepatic circulation of bile acids, potentially lowering bile acid levels in the liver and bloodstream—offering a novel treatment strategy for adult cholestatic liver diseases. The drug is currently being tested in Phase IIb trials: the VISTAS study for primary sclerosing cholangitis (PSC) and the VANTAGE study for primary biliary cholangitis (PBC). According to Mirum Pharmaceuticals' 2024 annual report, enrollment in the VISTAS study for PSC is expected to conclude in the second half of 2025, with top-line results anticipated in 2026. Enrollment for the VANTAGE study in PBC is projected to be completed in 2026. In November 2024, Mirum presented data on volixibat at the AASLD meeting. Linerixibat, another IBAT inhibitor, is an orally administered therapy under development for managing cholestatic pruritus linked to PBC, a rare autoimmune liver disorder. By blocking the reabsorption of bile acids, linerixibat aims to tackle the underlying mechanism of itch in these patients. Both the U.S. FDA and the European Medicines Agency (EMA) have granted orphan drug designation (ODD) to linerixibat for this indication. In November 2024, GSK reported positive top-line results from GLISTEN, its global Phase III trial assessing linerixibat in adults with PBC-related cholestatic pruritus. According to GSK's Q4 update, regulatory submissions in the U.S., Europe, and China are expected in the first half of 2025, followed by a U.S. regulatory decision and a Japan submission in the second half of the year. Regulatory decisions in Europe, Japan, and China are projected for 2026. The anticipated launch of these emerging therapies are poised to transform the IBAT inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the IBAT inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about IBAT inhibitors clinical trials, visit @ IBAT Inhibitors Treatment IBAT Inhibitors Overview IBAT inhibitors are typically taken orally, with most designed to remain in the gut and exhibit minimal absorption into the bloodstream. As a result, plasma levels often remain below detectable limits after either single or repeated dosing within the approved range. Nonetheless, newer IBAT inhibitors that are systemically absorbed are currently under development. A key drawback of gut-restricted IBAT inhibitors is their reduced effectiveness in patients with complete or near-total biliary obstruction, where bile acids do not adequately reach the small intestine. This is especially a concern in children, as biliary atresia is the leading cause of cholestasis in this population. To address this, systemically active ASBT inhibitors have been created. ASBTs are also found in the proximal tubules of the kidneys, where they help reabsorb small amounts of bile acids filtered through the glomerulus. IBAT Inhibitors Epidemiology Segmentation The IBAT inhibitors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases in Selected Indications for IBAT Inhibitors Total Eligible Patient Pool in Selected Indications for IBAT Inhibitors Total Treated Cases in Selected Indications for IBAT Inhibitors IBAT Inhibitors Report Metrics Details Study Period 2020–2034 IBAT Inhibitors Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report Primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), metabolic dysfunction-associated steatohepatitis (MASH), chronic constipation, biliary atresia, Alagille syndrome (ALGS), and others Key IBAT Inhibitors Companies GlaxoSmithKline, Mirum Pharmaceuticals, Ipsen, Albireo, Takeda, Ipsen Pharma, and others Key IBAT Inhibitors Linerixibat, Volixibat, Ritivixibat, LIVMARLI, BYLVAY/KAYFANDA, and others Scope of the IBAT Inhibitors Market Report IBAT Inhibitors Therapeutic Assessment: IBAT Inhibitors' current marketed and emerging therapies IBAT Inhibitors Market Dynamics: Conjoint Analysis of Emerging IBAT Inhibitor Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, IBAT Inhibitors Market Access and Reimbursement Discover more about IBAT inhibitors in development @ IBAT Inhibitors Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Key Events 5 Epidemiology Market Forecast Methodology of IBAT Inhibitors 6 IBAT Inhibitors Market Overview at a Glance in the 7MM 6.1 Market Share (%) Distribution by Therapies in 2025 6.2 Market Share (%) Distribution by Therapies in 2034 6.3 Market Share (%) Distribution by Indications in 2025 6.4 Market Share (%) Distribution by Indications in 2034 7 IBAT Inhibitor: Background and Overview 7.1 Introduction 7.2 The potential of IBAT inhibitors in Different Indications 7.3 Clinical Applications of IBAT Inhibitors 8 Target Patient Pool 8.1 Key Findings 8.2 Assumptions and Rationale: 7MM 8.3 Epidemiology Scenario in the 7MM 8.3.1 Total Cases in Selected Indications for IBAT Inhibitor in the 7MM 8.3.2 Total Eligible Patient Pool in Selected Indications for IBAT Inhibitor in the 7MM 8.3.3 Total Treated Cases in Selected Indications for IBAT Inhibitor in the 7MM 8.4 The US 8.5 EU4 and the UK 8.6 Japan 9 Marketed Drugs 9.1 Key Competitors 9.2 LIVMARLI (maralixibat chloride): Mirum Pharmaceuticals 9.2.1 Product Description 9.2.2 Regulatory Milestones 9.2.3 Other Developmental Activities 9.2.4 Clinical Development 9.2.5 Safety and Efficacy 9.2.6 Analyst Views 10 Emerging Therapies 10.1 Key Cross Competition 10.2 Volixibat: Mirum Pharmaceuticals 10.2.1 Drug Description 10.2.2 Others Developmental Activities 10.2.3 Clinical Trials Information 10.2.4 Safety and Efficacy 10.2.5 Analyst's View 10.3 Linerixibat: GlaxoSmithKline List of drugs to be continued in the final report... 11 IBAT Inhibitor: the 7MM Analysis 11.1 Key Findings 11.2 Key Market Forecast Assumptions 11.2.1 Cost Assumptions and Rebates 11.2.2 Pricing Trends 11.2.3 Analogue Assessment 11.2.4 Launch Year and Therapy Uptakes 11.3 Market Outlook 11.4 Attribute Analysis 11.5 Total Market Size of IBAT Inhibitor in the 7MM 11.6 The US Market Size 11.6.1 Total Market Size of IBAT Inhibitor in the US 11.6.2 Market Size of IBAT Inhibitors by Indication in the United States 11.6.3 Market Size of IBAT Inhibitor by Therapies in the US 11.7 EU4 and the UK Market Size 11.8 Japan Market Size 11 Unmet Needs 12 SWOT Analysis 13 KOL Views 14 Market Access and Reimbursement 14.1 The US 14.2 EU4 and the UK 14.3 Japan 15 Acronyms and Abbreviations 16 Bibliography 17 Report Methodology Related Reports Metabolic Dysfunction-associated Steatohepatitis Market Metabolic Dysfunction-associated Steatohepatitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MASH companies, including Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Akero Therapeutics, 89bio, Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics, Lipocine, Viking Therapeutics, Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai), Hepion Pharmaceuticals, Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences, Ionis Pharmaceuticals, Corcept Therapeutics, among others. Primary Sclerosing Cholangitis Market Primary Sclerosing Cholangitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PSC companies, including Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, Inc., NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, among others. Primary Biliary Cholangitis Market Primary Biliary Cholangitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PBC companies, including CymaBay Therapeutics, Zydus Therapeutics, Genfit, GlaxoSmithKline, Calliditas Therapeutics AB (Calliditas Therapeutics Suisse SA), Intercept Pharmaceuticals, Mirum Pharmaceuticals, Escient Pharmaceuticals, Gannex Pharma, Nanjing Chia-tai Tianqing Pharmaceutical, among others. Biliary Atresia Market Biliary Atresia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key biliary atresia companies, including Mirium Pharmaceuticals, Albireo, Intercept Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
